Literature DB >> 29498451

50 years with Down syndrome: A longitudinal study.

Janet Carr1, Suzanne Collins2.   

Abstract

BACKGROUND: A population sample of people with Down syndrome, studied from infancy, has now been followed up at the age of 50 years. From the original sample of 54, there were 27 still in the study at the age of 50, all but four of the losses resulting from deaths.
METHODS: Intelligence and language skills were tested and daily living skills assessed. Memory/cognitive deterioration was examined using two test instruments. Other aspects of the people's lives were examined via carers' reports.
RESULTS: Scores on verbal tests showed little change. Those on a non-verbal test, on self-help skills and on both memory tests showed some decline, even when the scores of those already suffering from dementia were discounted.
CONCLUSIONS: At the age of 50, those not already diagnosed with dementia showed some decline on most tests. While this may include scores of people who subsequently develop dementia, it may also reflect the normal ageing process in this population.
© 2018 The Authors. Journal of Applied Research in Intellectual Disabilities Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  50 years; Down syndrome; ageing; dementia; longitudinal

Mesh:

Year:  2018        PMID: 29498451     DOI: 10.1111/jar.12438

Source DB:  PubMed          Journal:  J Appl Res Intellect Disabil        ISSN: 1360-2322


  6 in total

1.  Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.

Authors:  Rachel Long; Montana L Drawbaugh; Charlene M Davis; Charles R Goodlett; Jane R Williams; Randall J Roper
Journal:  Complement Ther Med       Date:  2019-07-02       Impact factor: 2.446

2.  Language skills as a predictor of cognitive decline in adults with Down syndrome.

Authors:  Margaret B Pulsifer; Casey L Evans; Christy Hom; Sharon J Krinsky-McHale; Wayne Silverman; Florence Lai; Ira Lott; Nicole Schupf; Jiyang Wen; H Diana Rosas
Journal:  Alzheimers Dement (Amst)       Date:  2020-08-25

3.  Immunoassay-Amplified Responses Using a Functionalized MoS2-Based SPR Biosensor to Detect PAPP-A2 in Maternal Serum Samples to Screen for Fetal Down's Syndrome.

Authors:  Nan-Fu Chiu; Ming-Jung Tai; Devi Taufiq Nurrohman; Ting-Li Lin; Ying-Hao Wang; Chen-Yu Chen
Journal:  Int J Nanomedicine       Date:  2021-04-09

4.  Cognitive Function during the Prodromal Stage of Alzheimer's Disease in Down Syndrome: Comparing Models.

Authors:  Christy L Hom; Katharine A Kirby; Joni Ricks-Oddie; David B Keator; Sharon J Krinsky-McHale; Margaret B Pulsifer; Herminia Diana Rosas; Florence Lai; Nicole Schupf; Ira T Lott; Wayne Silverman
Journal:  Brain Sci       Date:  2021-09-16

5.  Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Authors:  Raza Jamal; Jonathan LaCombe; Roshni Patel; Matthew Blackwell; Jared R Thomas; Kourtney Sloan; Joseph M Wallace; Randall J Roper
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.752

Review 6.  Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease.

Authors:  Octavio García; Lisi Flores-Aguilar
Journal:  Front Cell Neurosci       Date:  2022-09-20       Impact factor: 6.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.